Search Results (47)

Background/Objectives: This study aimed to compare the effects of two different labiaplasty techniques, trim resection and modified wedge resection, on postoperative patient comfort, complication rates, and sexual function. Methods: Between 2021 and 2025, female patients who underwent labiaplasty using two different techniques at a tertiary care centre were retrospectively evaluated. The patients were divided into two equal groups: Group 1 underwent wedge resection, and Group 2 underwent trim resection. Postoperative outcomes were assessed at the first week, first month, and sixth month. Sexual and aesthetic outcomes were evaluated using the Female Sexual Function Index (FSFI) and the Female Genital Self-Image Scale (FGSIS). Results: A total of 40 female patients were included in the study. A statistically significant postoperative increase was observed in the total FGSIS and FSFI scores in both groups (p < 0.001 for all comparisons). Trim resection resulted in greater improvement in aesthetic satisfaction and body image, as reflected by higher postoperative FGSIS scores. In contrast, wedge resection produced more pronounced improvements in sexual function, particularly in the FSFI subdomains of arousal, orgasm, and satisfaction. Notably, the three patients who developed suture dehiscence at the first postoperative week had all undergone wedge resection and were active smokers. Conclusions: Both surgical techniques were effective in enhancing aesthetic satisfaction and sexual function following labiaplasty. While the trim technique appeared superior in improving aesthetic outcomes, the wedge technique provided greater benefits in specific sexual function parameters. Full article

Background/Objectives: Women’s sexual quality of life is a multidimensional construct shaped by individual, psychological, relational, and health-related factors. This exploratory cross-sectional study aimed to identify selected determinants of sexual functioning in young women, with a particular focus on partner relationships and sexual dysfunction symptoms within the couple. Methods: Data from 199 female university students aged 18–30 years, recruited via Facebook, were analyzed. Participants completed the Female Sexual Function Index (FSFI) and an author-designed questionnaire assessing sociodemographic variables, relationship characteristics, and self-perceived sexual difficulties in themselves and their partners. Descriptive statistics, bivariate analyses, and multivariable linear regression models were used to examine factors associated with the FSFI total and domain scores. Results: In this self-selected, non-representative sample, over 75% of women reported at least one self-perceived sexual difficulty, while 35.2% obtained FSFI scores at or below the established cutoff, indicating an increased risk of female sexual dysfunction rather than a confirmed diagnosis. In multivariable analysis, higher intercourse frequency, greater overall sexual satisfaction in the last 12 months, and fewer self-reported dysfunction symptoms emerged as the strongest independent predictors of higher FSFI total scores. Women who perceived premature ejaculation in their male partners tended to report lower orgasm and satisfaction domain scores, although this perception was not independently associated with the FSFI total score after adjustment for individual and relationship factors. Conclusions: These findings underline the role of both individual and relational factors in young women’s sexual functioning and support a holistic, couple-centred perspective in sexual health assessment. Full article

Background and Objectives: Sexual dysfunction (SD) is common in cancer but remains poorly characterized among patients receiving immune checkpoint inhibitors (ICIs). This study aimed to determine the prevalence and predictors of SD in ICI-treated patients using validated instruments. Materials and Methods: In this cross-sectional study, adults with histologically confirmed malignancies who received ≥ 3 cycles of ICIs and reported sexual activity were included. Sexual function was evaluated with the Arizona Sexual Experience Scale (ASEX) and the Golombok–Rust Inventory of Sexual Satisfaction (GRISS). Univariate and multivariate logistic regression analyses identified demographic and clinical predictors of SD. Results: Among 208 patients (median age 59 years; 35.1% female), SD prevalence was 66.3% by ASEX and 59.1% by GRISS. ASEX revealed impairment across five domains—sexual drive, psychological and physiological arousal, orgasm, and satisfaction—while GRISS indicated dysfunction mainly in impotence/orgasmic disorder, avoidance, and satisfaction subscales. In multivariate analysis, age ≥ 60 years (OR: 3.14, 95% CI 1.51–6.53, p = 0.002), female sex (OR: 3.19, 95% CI 1.31–7.74, p = 0.010), Eastern Cooperative Oncology Group (ECOG) performance status ≥ 1 (OR: 2.82, 95% CI 1.39–5.71, p = 0.004), ≥2 metastatic sites (OR: 3.08, 95% CI 1.53–6.19, p = 0.002), and later treatment lines (OR: 2.43, 95% CI 1.20–4.94, p = 0.013) independently predicted ASEX-defined SD. GRISS-based analysis revealed comparable outcomes, identifying ECOG ≥1 and higher metastatic burden as the most prominent predictors of SD, consistent with ASEX findings. Conclusions: SD affected nearly two-thirds of patients receiving ICIs. Female sex, later treatment lines, poor ECOG performance status, and higher metastatic burden were key determinants, emphasizing the importance of routine sexual health evaluation in cancer care. Full article

Olfaction is thought to have a role in intimate relationships and sexuality, despite the major roles that other senses, like sight, might have for human beings. Moreover, one of the specific symptoms of the COVID-19 infection, a disease largely impacting human sexuality at various levels, has been the absence of smell. This study aimed to examine the impact of olfaction on partner selection and on different phases of sexual response. Moreover, we evaluated whether the absence of smell could influence aspects of sexual function, such as orgasmic intensity, by comparing subjects with and without COVID-19 olfactory dysfunction. A group of 259 participants has been initially enrolled through social media. Of the 138 sexually active subjects included in the final analysis, 61 (44.2%) reported olfactory dysfunction (anosmia group) and 77 (55.8%) did not (no-anosmia group). Perceived orgasmic intensity was evaluated retrospectively at two time points—during the COVID-19 infection and in the four weeks preceding the evaluation—using the male and female versions of the Orgasmometer. The results revealed a significant interaction between time and olfactory condition, indicating opposite recovery trajectories. Participants without anosmia showed a significant improvement in orgasmic intensity post-COVID-19 infection; in contrast, the anosmia group reported a significant decline over the same period. Although the presence of anosmia was not a direct predictor of orgasmic intensity per se, it critically determined the orgasmic intensity evolution over time. These findings suggest that, beyond its perceived importance, the actual absence of olfaction may have a specific and negative long-term impact on core components of the sexual experience, such as the intensity of orgasm. Full article

Background: Female sexual dysfunction (FSD) is an underrecognized issue in women with systemic sclerosis (SSc), influenced by physical and psychological factors. Data on FSD in reproductive-age SSc patients, especially those with diffuse cutaneous SSc (dcSSc), remain limited. Objectives: This study aimed to determine the prevalence of FSD and identify its associated factors among reproductive-age women with SSc. Methods: A cross-sectional study (May 2019–March 2020) included sexually active women with SSc aged 18–45. Patients with surgical amenorrhea, prior radiation, hormonal contraceptive use within 12 weeks, or pregnancy were excluded. Sexual function was assessed using the Female Sexual Function Index (FSFI). Results: Among 27 women of reproductive age, 66.7% had the dcSSc subset. The mean age was 39.4 ± 5.2 years (range: 22–45 years), with a mean disease duration of 9.9 ± 7.9 years. FSD was identified in 51.9% of patients (95%CI: 31.9–71.3), with a higher prevalence in the dcSSc subset (71.4%) compared to limited cutaneous SSc (28.6%). Patients with FSD were more likely to be older at disease onset, exhibit telangiectasia, and have longer exposure to cyclophosphamide (CYC), although these findings were not statistically significant. Women with FSD showed significantly lower FSFI scores in arousal, lubrication, orgasm, sexual satisfaction, and total sexual function (p < 0.01 for all). Conclusions: FSD is highly prevalent among SSc women of reproductive age, particularly in those with dcSSc. Disease severity, older age at onset, and prolonged CYC treatment may contribute to the risk of FSD. Early recognition and management of sexual health issues are essential in this patient population. Full article

Background and Objectives: This study aims to investigate female sexual dysfunction (FSD) and the clinical, pathological, and social factors affecting it in women diagnosed with non-metastatic breast cancer. Materials and Methods: The study included patients over the age of 18 who were followed up between January 2020 and December 2024, diagnosed with breast cancer at least 12 months previously, and treated. The Female Sexual Function Index (FSFI) and its six subheadings (desire, arousal, lubrication, orgasm, satisfaction, and pain) were used to assess sexual dysfunction, and the Hospital Anxiety and Depression Scale (HADs) was used to assess depression. Results: FSD was identified in 86.6% of the 217 patients (mean FSFI score: 20.38). Among women undergoing breast cancer treatment, being over 45 years of age (p = 0.003) and the use of luteinizing hormone-releasing hormone (LHRH) agonists (p < 0.001) were significantly associated with reduced sexual desire. Conversely, premenopausal status (p = 0.012) was associated with increased sexual satisfaction. Independent risk factors for FSD included age, menopausal status, use of LHRH agonists, income level, and axillary dissection. Furthermore, depression was found to have a significant negative impact on sexual desire, lubrication, and orgasm. Conclusions: This study demonstrates that sexual dysfunction is common among women undergoing treatment for breast cancer and is influenced by numerous clinical and social factors. These findings highlight the need for strategic interventions to reduce the adverse effects of treatment processes on the sexual health of women with breast cancer. Full article

Background: Female Sexual Dysfunction (FSD) encompasses a range of conditions that can profoundly impact quality of life and intimate relationships. The primary classifications of FSD include female sexual interest and arousal disorder (FSIAD), genitopelvic pain and penetration disorder (GPPPD), female orgasmic disorder (FOD), and substance or medication-induced sexual dysfunction (SM-ISD). Despite its prevalence, FSD is often underdiagnosed and undertreated. Objectives: This scoping review follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evaluate the existing literature on both U.S. Food and Drug Administration (FDA)-approved and off-label pharmacotherapies for FSD by study type, outcomes, and limitations. Eligibility Criteria: Eligible studies comprised randomized controlled trials (RCTs), systematic reviews, and cohort studies involving adult women (≥18 years) with any subtype of FSD. These studies assessed pharmacologic interventions against a comparator and reported at least one treatment efficacy outcome. Studies outside this scope were excluded. Sources of Evidence: A 25-year literature search was conducted using PubMed/MEDLINE, the Cochrane Library, reference lists of relevant articles, academic handbooks, and targeted journals. Charting Methods: Three independent reviewers screened and extracted data. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Findings were organized into summary tables and categorized by pharmaceutical agent, pertinent study information, outcomes, and limitations. Results: A total of 44 human-based pharmacologic studies met inclusion criteria. FDA-approved agents were the most thoroughly studied pharmacotherapies. Hormonal, topical, and adjunctive agents demonstrated less robust evidence. Heterogeneity in outcome measures and inadequate long-term data were common limitations. Conclusions: Pharmacologic treatment for FSD shows promise but requires further research. Individualized, multifaceted care is essential for optimizing FSD outcomes. Full article

Objective: Sexual dysfunction (SD) is a prevalent but frequently overlooked condition that adversely affects women’s quality of life and psychological well-being. This study aimed to examine the relationship between SD and depression, anxiety, and stress levels during premenopausal, pregnancy, and postmenopausal. Methods: This prospective, cross-sectional study included 300 women aged 18–70 who presented with SD symptoms to a tertiary care gynecology outpatient clinic. Participants were categorized into premenopausal, pregnant, and postmenopausal groups. Sexual function was assessed using the Female Sexual Function Index (FSFI), and psychological status was evaluated with the Depression Anxiety and Stress Scale (DASS-21). Univariate and multivariate logistic regression analyses were conducted to identify risk factors associated with SD. Results: The results showed that SD prevalence varied across life stages, with the highest rate (96%) observed in postmenopausal women. Significant decreases were found in all FSFI subscales, particularly lubrication and orgasm, during the postmenopausal period (p < 0.001). Although DASS-21 total scores did not differ significantly between groups (p = 0.227), severe stress was more prevalent in premenopausal women (p = 0.018). Univariate logistic regression revealed that older age, higher parity, and menopause increased SD risk (p < 0.001), while employment (p = 0.006), higher education (p = 0.012), and pregnancy (p < 0.001) were protective factors. Multivariate analysis identified parity as the only independent variable significantly increasing SD risk (p = 0.011). Weak but significant negative correlations were found between FSFI total score and DASS-21 total (r = −0.137, p = 0.018), anxiety (r = −0.135, p = 0.019), and depression (r = −0.176, p = 0.002) scores. Conclusion: These findings highlight the importance of individualized assessment and treatment approaches for women’s sexual health across different life stages, considering the influence of various biological, psychological, and social factors. Full article

Background: Research has underscored that the attachment type could explain the association between sexual behavior and relational satisfaction. This study aimed to explore the relationship between attachment type, sexual function, and relationship characteristics of adult women. Methods: This cross-sectional study included an a priori calculated sample of 304 women, who completed the Female Sexual Function Index, the Relationship Assessment Scale, and the Experiences in Close Relationships—Revised Scale. Results: Women with anxious attachment types reported higher levels of sexual arousal, orgasm, and satisfaction compared to other types, suggesting that emotional insecurity may intensify sexual intimacy within relationships. Overall, relational satisfaction was positively associated with various aspects of sexual function, particularly arousal and orgasmic function. Specifically, anxious attachment was associated with higher levels of sexual arousal, orgasm, and overall satisfaction, emphasizing the impact of relational dynamics on sexual well-being. Conclusions: The findings of this study highlight the significant role of attachment patterns and relational satisfaction in shaping women’s sexual function and experiences. The results suggest that therapeutic interventions aiming at the improvement of women’s sexual health should consider both attachment type and relational satisfaction as these factors are integral to the quality of sexual experience. Full article

Background/Objectives: Stress urinary incontinence (SUI) is a common condition affecting sexual function, exercise activities, and quality of life, accompanied by psychological distress. The treatment of SUI includes conservative and surgical treatment which comprises tensions-free vaginal tapes in the form of retropubic (TVT) and transobturator tape (TOT or TVT—O). The TVT procedure is considered the gold standard, but the TOT procedure is a safe alternative due to a lower rate of bladder and bowel complications. The aim of this study is to evaluate the long-term effects of the surgical treatment of the TOT procedure after 36 months of follow-up on the sexuality of women with SUI. Methods: In the long-term evaluation, 3 years after surgery, 45 women with medical records sufficient for analysis participated in the project. The international standardized Female Sexual Function Index (FSFI) self-administered questionnaire was completed three times: before the surgery, 12 months after surgery, and 3 years after surgery. Results: Domain scores for arousal, lubrication, orgasm, and total score were lower in the follow-up group than before and after the surgery. The pain domain was the highest in the after-surgery group, slightly lower in the before-surgery group, and the lowest in the follow-up group. All the abovementioned differences were statistically significant. Conclusions: Three years after the surgical treatment of SUI, the results of our study patients deteriorated, especially in arousal, lubrication, and orgasm assessments, compared to outcomes 12 months after the procedure. In addition, the total FSFI score was lower 36 months after the surgery than the year before the surgery and lower than before the procedure. Also, pain during intercourse was more frequently reported, as opposed to the result year after the surgery, which was lower than before the operation. Full article

Objectives: The aim of the study was to analyze and compare the possible effect of cervical conization and the loop electrosurgical excision procedure (LEEP) on female sexual function up to one year after intervention, as existing studies provide incoherent results. Methods: This prospective cohort study enrolled patients who underwent either LEEP (n = 35) or surgical conization of the cervix (n = 44). Patients completed the questionnaire before the intervention and at three, six, and twelve months after the end of the postoperative period. The questionnaire included the Polish version of the Female Sexual Function Index (FSFI) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire of Cancer Patients with the module Cervix-24. Results: In the LEEP group, significant deterioration was observed in the FSFI orgasm subscale after three and six months in comparison to the baseline (3.98 ± 2.08 vs. 3.19 ± 2.29 vs. 3.09 ± 2.24; p < 0.02). The difference in the orgasm subscale compared to the baseline score was not reported after twelve months of follow-up. In the surgical conization group, significant deterioration was observed in the general FSFI score between the baseline and three months after (22.37 ± 12.38 vs. 20.82 ± 12.02; p < 0.003) and in the arousal subscale between the baseline and three months after (3.69 ± 2.14 vs. 3.01 ± 2.02; p < 0.001). In the orgasm subscale, there was a significant improvement between three and twelve months of observation (3.05 ± 2.22 vs. 3.63 ± 2.29; p < 0.003). A significant deterioration was observed in the sexual activity subscale of the EORTC QLQ-C30 + CX24 between baseline and after three months (49.42 ± 36.12 vs. 39.09 ± 36.81; p < 0.03). All reported deteriorations had a tendency to resolve within twelve months of observation. Conclusions: Both LEEP and surgical conization of the cervix seem to have a mild, transient negative impact on female sexual function, which normalizes one year after the procedure. Long-term consequences of both procedures are similar. Further research with larger sample sizes is necessary to confirm these findings. Full article

Background/Objectives: Female sexual dysfunction (FSD) involves persistent issues with desire, arousal, orgasm, or pain during intercourse. The Female Sexual Function Index (FSFI), a validated 19-item questionnaire, is widely used to assess FSD. Childbirth, particularly vaginal delivery with perineal trauma, can increase FSD risk, with 41–83% of women affected at six months postpartum. However, early postpartum FSD remains underexplored. This study examines FSD risk factors in first-time mothers delivering vaginally, using longitudinal FSFI assessments before and after the delivery. Methods: A prospective observational study was conducted involving 80 primiparous women who delivered vaginally. The FSFI questionnaire was provided before childbirth and three months postpartum. We compared the group of women who developed early FSD after delivery (N = 45) with those with a normal FSFI score (>26.6). Results: Three months after vaginal delivery, participants exhibited a significant decrease in overall FSFI scores (−9.61 [95%CI: −11.6; −7.6]; p = 0.008). A total of 45 patients (56.2%) developed early FSD. Marital status emerged as a significant factor, with marriage acting as a protective factor (OR 0.27 [95%CI 0.05–1.24]; p = 0.044). Clitoral and periclitoral tears were associated with a higher risk of FSD than high-degree perineal lacerations (OR 3.02 [95%CI 1.56–6.24]; p = 0.021). Conclusions: At three months post vaginal delivery, primiparous women face a relevant risk of developing transient sexual dysfunction. Marital status and type of perineal tears are identified as key factors influencing postpartum sexual function. Further research is warranted to explore these factors comprehensively and provide timely clinical and psychological support to couples navigating the challenges of early family life. Full article

Background: This study analyzes the effects of bariatric surgery on female sexual function, assessed using the Female Sexual Function Index (FSFI), and explores the impact of adherence to the Mediterranean diet during the postoperative period. Patients and methods: A retrospective observational study was conducted using a prospectively collected database, including heterosexual women with morbid obesity undergoing bariatric procedures. The FSFI questionnaire was applied before the intervention and 24 months after surgery. Adherence to the Mediterranean diet was evaluated using the PREDIMED questionnaire. Results: Among the 240 participants, 70.8% presented preoperative sexual dysfunction, which decreased to 20.5% two years post-surgery. Significant improvements were observed in all FSFI domains except for pain. Good adherence to the Mediterranean diet was associated with higher scores in the lubrication, orgasm, and satisfaction domains. Conclusions: Bariatric surgery significantly improves female sexual function, with the Mediterranean diet enhancing these benefits during the postoperative period. Future studies must investigate additional variables such as psychological factors, physical activity, and other lifestyle changes that may also influence sexual function. Full article

Many primary studies and reviews have been published on the influence of chronic diseases (CDs) on sexual dysfunction (SD), but CDs not involving the genitals are less well represented in the literature. Aim: To determine the prevalence of SD in patients with non-genital CD and assess the overall impact on sexual functioning. Methods: An umbrella review was performed of published systematic reviews on the relationship between the occurrence of CDs not involving the genitals and patients’ sexual functioning, following the PRISMA guidelines. PubMed, EMBASE, the Cochrane Library, PsycInfo, Scopus, and CINAHL were used to find publications for inclusion in the review, with two independent researchers performing the search and selection of articles, data extraction, and quality assessment. The relative risk (RR) or odds ratio (OR) with 95% confidence was used as an indicator of the association between CD and SD across studies. The quality of studies included in the review was assessed using Amstar-2. Outcomes: Forty-three systematic reviews, thirty of which included a meta-analysis, met the inclusion criteria, representing a total of 880,586 patients (756,629 (85.9%) men, 68,388 (7.8%) women, and 55,569 (6.3%) unspecified). Results: Among men, CD is associated with erectile dysfunction, and among females, with lower levels of desire, arousal, lubrication, orgasm, and sexual satisfaction and with increased pain during intercourse. For both men and women, depression, anxiety, and fatigue are also reported, while women with CD are more affected by a poor body image than men. Clinical implications: Patients with CD, especially females, should be more routinely assessed for the impact of their condition on sexual functioning. The impact of CD on men’s sexuality has been extensively studied in terms of erectile capacity, but other aspects of their sexuality are largely neglected. Strengths and limitations: This is the first umbrella review to bring together the documented findings regarding sexual dysfunction among patients with various non-genital CDs. While the heterogeneity of the CDs makes the study unique and clinically relevant, it renders the interpretation of the results more difficult. The overrepresentation of men in existing studies reflects the current state of research but limits the applicability of the findings for women. Conclusions: Women and men with non-genital CDs can suffer from SD or reduced sexual function. Health professionals should pay more attention to managing these sexual disorders, even when the disease does not affect the genitals. Full article

Background: The female orgasm is a highly understudied phenomenon that is linked to both wellbeing and relationship satisfaction in women. Although orgasm has been associated with interoception—the sense of the physiological condition of the body—very few studies have directly examined the influence that interoception has on orgasm. Objectives: This study investigates how the subjective experience of one’s interoceptive capacities (called interoceptive awareness) is associated with self-reported orgasm frequency and satisfaction in people who identify as women. Methods: In a dataset of 318 women, orgasm frequency and satisfaction were both rated significantly higher for solitary as compared to partnered sexual experiences. Results: Analysis of how dimensions of interoceptive awareness correlated with orgasm frequency and satisfaction showed that (1) ‘Noticing’ predicted orgasm frequency (but not satisfaction) across both solitary and partnered interactions, (2) ‘Attention Regulation’ predicted greater frequency and satisfaction of solitary orgasm (but not partnered interactions), and (3) ‘Body Trusting’ predicted orgasm satisfaction (but not frequency) across both solitary and partnered contexts. Conclusions: Findings underscore the importance of moving beyond orgasmic dysfunction research by investigating how interoception is associated with healthy—and potentially even optimal—orgasmic functioning in women. Full article